Raymond James Trust N.A. increased its holdings in shares of Danaher Co. (NYSE:DHR) by 5.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 14,469 shares of the conglomerate’s stock after acquiring an additional 703 shares during the period. Raymond James Trust N.A.’s holdings in Danaher were worth $3,214,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Epiq Partners LLC grew its position in shares of Danaher by 8.9% during the 4th quarter. Epiq Partners LLC now owns 14,934 shares of the conglomerate’s stock valued at $3,317,000 after acquiring an additional 1,220 shares during the period. Mirova grew its holdings in Danaher by 8.6% in the third quarter. Mirova now owns 197,237 shares of the conglomerate’s stock valued at $42,471,000 after purchasing an additional 15,617 shares during the period. Kore Private Wealth LLC grew its holdings in Danaher by 9.9% in the third quarter. Kore Private Wealth LLC now owns 1,124 shares of the conglomerate’s stock valued at $242,000 after purchasing an additional 101 shares during the period. Kestra Advisory Services LLC acquired a new stake in Danaher in the 3rd quarter valued at $6,678,000. Finally, Rehmann Capital Advisory Group acquired a new stake in Danaher in the 3rd quarter valued at $738,000. Hedge funds and other institutional investors own 69.16% of the company’s stock.
In other news, SVP Daniel Raskas sold 28,389 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The shares were sold at an average price of $234.50, for a total value of $6,657,220.50. Following the transaction, the senior vice president now directly owns 38,850 shares in the company, valued at approximately $9,110,325. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Robert S. Lutz sold 24,594 shares of the company’s stock in a transaction on Friday, October 23rd. The stock was sold at an average price of $233.19, for a total value of $5,735,074.86. Following the transaction, the chief accounting officer now owns 43,544 shares in the company, valued at $10,154,025.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,385 shares of company stock worth $25,081,562. Corporate insiders own 11.70% of the company’s stock.
Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 22nd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.36. Danaher had a net margin of 18.05% and a return on equity of 12.94%. The company had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.51 billion. During the same period in the previous year, the business posted $1.06 EPS. Danaher’s revenue was up 17.1% on a year-over-year basis. As a group, equities research analysts predict that Danaher Co. will post 6.03 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Monday, December 28th will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Thursday, December 24th. Danaher’s dividend payout ratio (DPR) is presently 16.29%.
Several analysts have recently issued reports on DHR shares. Royal Bank of Canada lowered shares of Danaher from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $273.00 to $234.00 in a research report on Wednesday, November 25th. Wells Fargo & Company reiterated a “buy” rating and issued a $234.00 price objective on shares of Danaher in a report on Tuesday, September 29th. Needham & Company LLC lifted their price objective on Danaher from $209.00 to $272.00 in a report on Tuesday, October 27th. Robert W. Baird lifted their price target on Danaher from $205.00 to $252.00 and gave the stock an “outperform” rating in a research note on Friday, October 23rd. Finally, The Goldman Sachs Group initiated coverage on shares of Danaher in a research note on Wednesday, December 2nd. They set a “buy” rating and a $250.00 target price on the stock. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $219.44.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Read More: Put Option
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.